Phase 2 N=42 Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
Lymphoma
Primary: Objective Response Rate (ORR) — 88.1 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=221 A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
Dermatitis, Atopic · Eczema
Primary: Mean Percentage Change From Baseline in EASI at Week 16 — -84.41; -76.03; -78.93; -62.65 Percent Change — p=0.003
Phase 2 N=16 Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
Primary: Percent Change From Baseline in Lactate Dehydrogenase (LDH) Level at Day 92 — -53.59; -25.56; -43.58 Percent change from Baseline
Phase 2 N=98 Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine
Healthy Volunteer
Primary: Microneutralization Titers — 0.769; 1.313; 1.716; 1.333 Log2 Fold Change
Phase 2 N=45 Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
Bladder Urothelial Carcinoma In Situ · Recurrent Bladder Urothelial Carcinoma · Stage 0a Bladder Cancer AJCC v8
Primary: Trial Recruitment: Number of Participants Eligible, Enrolled, and Not Enrolled — 45; 0; 3; 2 Participants
Phase 2 N=122 Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
Advanced Colorectal Cancer
Primary: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human…
Phase 2 N=61 The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC
Metastatic Castrate Resistant Prostate Cancer (mCRPC) · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Primary: Evaluate the Safety and Tolerability of GT0918 and Select the RP2D for Future Clinical Trial Study. — 28; 29; 6; 12 Participants
Phase 2 N=22 Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis
Trochanteric Bursitis
Primary: Change in Pain From Baseline as Assessed by the Numeric Pain Rating Scale (NPRS) Score — -2.25 score on a scale
Phase 2 N=90 Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)
Brain Cancer
Primary: Time to Cognitive Failure — 7.7; 4.9 months — p=.74
Phase 2 N=206 Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room
Hypotension
Primary: Change in Mean Arterial Pressure (MAP) From the Baseline MAP — 76.3; 76.9; 73.5; 76.3 mm Hg — p=<0.001
Phase 2 N=60 Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Dose-limiting-toxicities (DLTs) (Phase 1) — 0; 0; 0; 0 Participants
Phase 2 N=20 Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
Metastatic Malignant Neoplasm in the Bone · Metastatic Malignant Neoplasm in the Lung · Salivary Gland Carcinoma
Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 — 3; 1; 2; 6 Participants
Phase 2 N=33 PK and Safety of SI-722 in IC/BPS
Interstitial Cystitis · Bladder Pain Syndrome
Primary: Maximum Plasma Concentration (Cmax) for SI-722 — NA; NA; NA; NA ng/mL
Phase 2 N=75 A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia
Primary: Incidence of Adverse Events (AEs) (Safety and Tolerability) — 74; 74; 72; 27 Participants
Phase 2 N=105 A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP
Immune Thrombocytopenic Purpura (ITP)
Primary: Percentage of Participants With Sustained Response Off Treatment (SRoT) by 12 Months — 30.5 Percentage of participants — p=<0.0001